ENLV

Enlivex Therapeutics Ltd.

Price

$1.52

return (12m)

-90.62%

p/e

0.02

p/bv

0.01

DIVIDEND YIELD

0.00%

ENLV price

Enlivex Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment ENLV

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-63.02%

3 months

-87.04%

1 year

-90.62%

2 years

-91.76%

5 years

-99.15%

10 years

-99.85%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals ENLV

Valuation

P/E

0.02

Sector -0.28

Industry 5.53

P/BV

0.01

Sector 1.94

Industry 3.62

P/Revenue (PSR)

Sector 1.67

Industry 3.22

EV/EBITDA

-3.18

Sector -55.30

Industry -15.42

EV/EBIT

-3.14

Sector -488.87

Industry -265.25

P/EBITDA

-1.65

Sector -185.04

Industry -4.69

P/EBIT

-1.61

Sector -222.22

Industry -73.65

P/Total Assets

0.01

Sector 0.92

Industry 1.38

P/Net Current Assets

0.02

Sector -479.54

Industry -3.14

P/Working Capital

0.01

Sector -957.77

Industry 5.70

EPS

77.22

Sector -0.78

Industry -0.23

BVPS

120.93

Sector 3.74

Industry 8.46

Efficiency

Gross Margin

0.00%

Sector 48.28%

Industry 54.33%

EBITDA Margin

Sector -5,407,515.68%

Industry -5.60%

EBIT Margin

Sector -62.93%

Industry -9.94%

Operating Margin

0.00%

Sector -23.12%

Industry -5.68%

Net Profit Margins

0.00%

Sector -27.40%

Industry -9.68%

Asset Turnover

0.00

Sector 0.13

Industry 0.12

Profitability

ROE

63.85%

Sector -31.88%

Industry -25.41%

ROA

53.10%

Sector -28.23%

Industry -6.72%

ROIC

-2.02%

Sector -315.71%

Industry -7.54%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

193.26

Sector 1.85

Industry 2.52

Net Debt / EBITDA

0.99

Sector -42.46

Industry 0.16

Net Debt / EBIT

0.98

Sector -37.26

Industry -92.34

Net Debt / Equity

0.00

Sector -1.04

Industry 0.22

Gross Debt / Equity

0.00

Sector -0.72

Industry 0.38

Equity/Assets

0.83

Sector 0.43

Industry 0.46

Liabilities/Assets

0.17

Sector 0.48

Industry 0.51

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

FAIR VALUE OF Enlivex Therapeutics ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$1.52

Fair Value

$458.38

Upside Return potential.

30,056.41%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals ENLV

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
ENLV Enlivex Therapeutics Ltd.	$1.52	-90.35%	0.00%	0.02	0.01	63.85%	0.00%
LLY Eli Lilly and Compay	$1,233.66	69.04%	0.52%	41.58	-	-%	33.53%
SNY Sanofi	$46.02	-6.85%	3.87%	7.43	1.37	18.43%	13.81%
GSK GlaxoSmithKline PLC	$52.08	35.53%	3.42%	15.92	4.50	28.24%	14.54%
CRMD CorMedix Inc.	$8.56	-37.47%	0.00%	3.45	1.40	40.62%	40.49%
AMPH Amphastar Pharmaceuticals Inc.	$21.98	-27.93%	0.00%	12.05	1.23	10.23%	10.76%
RDY Dr. Reddy's Laboratories Ltd.	$12.34	-14.35%	0.68%	27.69	2.50	9.03%	10.14%
ISRG Intuitive Surgical Inc.	$371.84	-21.91%	0.00%	41.88	7.23	17.26%	28.62%
NVS Novartis AG	$159.98	28.44%	1.96%	28.21	7.75	27.47%	26.57%
TMO Thermo Fisher Scientific Inc.	$628.15	26.18%	0.29%	33.36	4.42	13.26%	15.08%
ABT Abbott Laboratories	$116.13	-9.73%	2.33%	33.60	3.57	10.61%	11.65%
MDT Medtronic PLC	$91.14	2.28%	3.09%	24.60	2.36	9.59%	13.20%
BSX Boston Scientific Corp.	$49.86	-52.56%	0.00%	17.71	0.00	-%	19.57%
TMDX TransMedics Group Inc.	$93.60	-21.90%	0.00%	21.60	6.32	29.28%	22.69%
IDXX IDEXX Laboratories Inc.	$550.01	-14.80%	0.00%	38.78	27.41	70.67%	25.03%
RMD ResMed Inc.	$236.59	-18.43%	1.04%	22.12	5.18	23.41%	27.44%
DHR Danaher Corporation	$215.97	5.49%	0.67%	37.88	2.88	7.61%	15.95%
HCA HCA Healthcare Inc.	$428.76	6.57%	0.70%	12.08	-29.56	-244.72%	10.07%
COHR Coherent Inc.	$288.14	220.51%	0.00%	115.66	4.75	4.11%	6.85%
PHG Koninklijke Philips NV	$27.43	0.60%	3.68%	20.31	1.99	9.80%	6.30%
SYK Stryker Corp.	$330.59	-15.06%	1.06%	33.67	5.23	15.55%	14.43%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

ENLV Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Enlivex Therapeutics

Enlivex Therapeutics Ltd.

Average Investor10 user rating

4.0 (0 people)

United States

14 years

Founded: 2012

2014

Time since IPO - 12 years

50

Employees

Enlivex Therapeutics Ltd. (United States) is listed on the Nasdaq and has a market capitalization of $24.16 million, with shareholders equity totaling $1.93 billion.

The company employs approximately 50 people and operates in the Health sector, within the Pharmaceutical Products industry.

Over the past 12 months, Enlivex Therapeutics Ltd. reported $- in revenue, generating net income of $1.24 billion.

Key financial metrics include a P/E ratio of 0.02, a price-to-book (P/B) ratio of 0.01, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker ENLV.

Market cap

$24.16 million

Net worth

$1.93 billion

$1,934,950,000.00

Assets

$2.33 billion

$2,327,000,000.00

Total Shares Outstanding

16.00 million

16,000,000

Average Daily Trading Volume

$230.18 Thousand

$230,182.18

Sector

Health

Industry

Pharmaceutical Products

ENLV

ENLV revenue and profits

Financial Results ENLV

DRAG THE FRAME TO SEE MORE DATA

ENLV cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

CVS - CVS Health

$92.90 33,94% (12M)

P/E

-0.84

2.83%

ROE

-178.93%

P/BV

1.51

CI - Cigna

$279.32 --4,41% (12M)

P/E

10.77

2.20%

ROE

16.04%

P/BV

1.73

CNC - Centene

$65.00 126,80% (12M)

P/E

-6.35

0.00%

ROE

-22.56%

P/BV

1.43

HUM - Humana

$389.71 32,28% (12M)

P/E

35.82

0.92%

ROE

6.72%

P/BV

2.41

SNY - Sanofi

$46.02 --4,90% (12M)

P/E

7.43

3.87%

ROE

18.43%

P/BV

1.37

LLY - Eli Lilly

$1,233.66 69,47% (12M)

P/E

41.58

0.52%

ROE

P/BV

HCA - HCA Healthcare

$428.76 7,37% (12M)

P/E

12.08

0.70%

ROE

-244.72%

P/BV

-29.56

NVS - Novartis

$159.98 28,78% (12M)

P/E

28.21

1.96%

ROE

27.47%

P/BV

7.75